Details of the Drug

General Information of Drug (ID: DMXNZM4)

Drug Name

Oxazepam

Synonyms

Abboxampam; Abboxapam; Adumbran; Alepam; Ansioxacepam; Anxiolit; Aplakil; Astress; Azutranguil; Azutranquil; Bonare; Drimuel; Droxacepam; Durazepam; Hilong; Isodin; Lederpam; Limbial; Murelax; Nesontil; Noctazepam; Nortemazepam; Nozepam; Ossazepam; Oxanid; Oxazepamum; Oxazipam; Oxozepam; Pacienx; Praxiten; Propax; Psicopax; Psiquiwas; QUEN; Quilibrex; Rondar; Sedigoa; Serax; Serenal; Serenid; Serepax; Seresta; Serpax; Sigacalm; Sobril; Tacepam; Tarchomin; Tazepam; Uskan; Vaben; Zaxopam; Anxiolit retard; Ossazepam [DCIT]; P acienx; CB 8092; DF2371850; O5254_SIGMA; Wy 3498; Z 10 tr; Alepam (TN); Apo-astress; Hi-Long; Medopam (TN); Murelax (TN); N-Desmethyltemazepam; Noripam (TN); Oxa-puren; Oxazepamum [INN-Latin]; Purata (TN); Ro 5-6789; Serax (TN); Serenid-D; Serepax (TN); WY-3498; Wy-3498 stic; Z10-Tr; Ox-Pam (TN); Tranquo-buscopan-wirkstoff; Oxazepam (JAN/USP/INN); Oxazepam [USAN:INN:BAN:JAN]; (+-)-7-Chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one; (+-)-Oxazepam; (RS)-Oxazepam; 1,3-Dihydro-7-chloro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one; 1,3-Dihydro-7-chloro-3-hydroxy-5-phenyl-3H-1,4-benzodiazepin-2-one; 7-Chloro-1,3-dihydro-3-hydroxy-5-phenyl-1,4(2H)-benzodiazepin-2-one; 7-Chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepin-2-one; 7-Chloro-1,3-dihydro-3-hydroxy-5-phenyl-2H-1,4-benzodiazepine-2-one; 7-Chloro-3-hydroxy-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one; 7-chloro-3-hydroxy-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one

Indication

Disease Entry	ICD 11	Status	REF
Anxiety disorder	6B00-6B0Z	Approved	[1], [2]

Therapeutic Class

Hypnotics and Sedatives

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

286.71

Topological Polar Surface Area (xlogp)

2.2

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 450,000 mg/L [3]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 3 h [3]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Bioavailability: 97% of drug becomes completely available to its intended biological destination(s) [5]
Clearance: The drug present in the plasma can be removed from the body at the rate of 1.1 mL/min/kg [6]
Elimination: Oxazepam is primarily eliminated in the urine as its glucuronide metabolite, with the feces containing approximately 21% of the unchanged drug [7]
Half-life: The concentration or amount of drug in body reduced by one-half in 8.2 hours [3]
Metabolism: The drug is metabolized via UGT2B15 [3]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 6.97544 micromolar/kg/day [8]
Unbound Fraction: The unbound fraction of drug in plasma is 0.04% [6]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.59 L/kg [6]
Water Solubility: The ability of drug to dissolve in water is measured as 0.045 mg/mL [4]

Chemical Identifiers

Formula: C15H11ClN2O2
IUPAC Name: 7-chloro-3-hydroxy-5-phenyl-1,3-dihydro-1,4-benzodiazepin-2-one
Canonical SMILES: C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O
InChI: InChI=1S/C15H11ClN2O2/c16-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)18-15(20)14(19)17-12/h1-8,15,20H,(H,17,19)
InChIKey: ADIMAYPTOBDMTL-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 4616
ChEBI ID: CHEBI:7823
CAS Number: 604-75-1
DrugBank ID: DB00842
TTD ID: D09LDR
INTEDE ID: DR1214
ACDINA ID: D00499

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Translocator protein (TSPO)	TTPTXIN	TSPO_HUMAN	Agonist	[9]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[10]
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Substrate	[11]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[12]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[12]
UDP-glucuronosyltransferase 2B7 (UGT2B7)_{Main DME}	DEB3CV1	UD2B7_HUMAN	Substrate	[13]
Cytochrome P450 3A43 (CYP3A43)	DEO1IE3	CP343_HUMAN	Substrate	[12]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Oxazepam (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Sodium bicarbonate	DMMU6BJ	Minor	Altered absorption of Oxazepam due to GI dynamics variation caused by Sodium bicarbonate.	Acidosis [5C73]	[64]
Oliceridine	DM6MDCF	Major	Additive CNS depression effects by the combination of Oxazepam and Oliceridine.	Acute pain [MG31]	[65]
Dihydrocodeine	DMB0FWL	Major	Additive CNS depression effects by the combination of Oxazepam and Dihydrocodeine.	Chronic pain [MG30]	[66]
Remifentanil	DMZTXCH	Major	Additive CNS depression effects by the combination of Oxazepam and Remifentanil.	Corneal disease [9A76-9A78]	[65]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Oxazepam and Esketamine.	Depression [6A70-6A7Z]	[67]
SODIUM CITRATE	DMHPD2Y	Minor	Altered absorption of Oxazepam due to GI dynamics variation caused by SODIUM CITRATE.	Discovery agent [N.A.]	[64]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Oxazepam caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[68]
Didanosine	DMI2QPE	Minor	Altered absorption of Oxazepam due to GI dynamics variation caused by Didanosine.	Human immunodeficiency virus disease [1C60-1C62]	[64]
Probenecid	DMMFWOJ	Minor	Decreased metabolism of Oxazepam caused by Probenecid.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[69]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Oxazepam caused by PF-06463922 mediated induction of UGT.	Lung cancer [2C25]	[67]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Oxazepam and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[70]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Oxazepam and Lasmiditan.	Migraine [8A80]	[71]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Oxazepam and Flibanserin.	Mood disorder [6A60-6E23]	[72]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Oxazepam and Thalidomide.	Multiple myeloma [2A83]	[73]
Teduglutide	DMYOAKS	Moderate	Altered absorption of Oxazepam caused by Teduglutide.	Neonatal malabsorption syndrome [KB89]	[74]
Levomethadyl Acetate	DM06HG5	Major	Additive CNS depression effects by the combination of Oxazepam and Levomethadyl Acetate.	Opioid use disorder [6C43]	[66]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Oxazepam and Apraclonidine.	Optic nerve disorder [9C40]	[75]
Oxymorphone	DM65AGJ	Major	Additive CNS depression effects by the combination of Oxazepam and Oxymorphone.	Pain [MG30-MG3Z]	[65]
Diflunisal	DM7EN8I	Minor	Increased plasma concentration of Oxazepam and Diflunisal due to competitive binding of plasma proteins.	Pain [MG30-MG3Z]	[76]
Levorphanol	DMGS80V	Major	Additive CNS depression effects by the combination of Oxazepam and Levorphanol.	Pain [MG30-MG3Z]	[65]
Dezocine	DMJDB0Y	Major	Additive CNS depression effects by the combination of Oxazepam and Dezocine.	Pain [MG30-MG3Z]	[65]
Nalbuphine	DMOSQGU	Major	Additive CNS depression effects by the combination of Oxazepam and Nalbuphine.	Pain [MG30-MG3Z]	[65]
Buprenorphine	DMPRI8G	Major	Additive CNS depression effects by the combination of Oxazepam and Buprenorphine.	Pain [MG30-MG3Z]	[77]
Hydrocodone	DMQ2JO5	Major	Additive CNS depression effects by the combination of Oxazepam and Hydrocodone.	Pain [MG30-MG3Z]	[65]
Amiodarone	DMUTEX3	Minor	Potentiate the pharmacologic effects by the combination of Oxazepam and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[78]
-----------


⏷ Show the Full List of 25 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
Benzyl alcohol	E00010	244	Antimicrobial preservative; Solvent
Butylparaben	E00142	7184	Antimicrobial preservative
D&C red no. 28	E00491	6097185	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
methylparaben	E00149	7456	Antimicrobial preservative
Propyl 4-hydroxybenzoate	E00141	7175	Antimicrobial preservative
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Carmellose sodium	E00625	Not Available	Disintegrant
Edetate calcium disodium	E00487	6093170	Complexing agent
Ferrosoferric oxide	E00231	14789	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Lithol rubin BCA	E00607	135423095	Colorant
Magnesium stearate	E00208	11177	lubricant
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Sodium propionate	E00445	2723816	Antimicrobial preservative
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
--------------------


⏷ Show the Full List of 19 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Oxazepam 10 mg capsule	10 mg	Oral Capsule	Oral
Oxazepam 30 mg capsule	30 mg	Oral Capsule	Oral
Oxazepam 15 mg capsule	15 mg	Oral Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7253).
2	What every dentist should know about the "z-sedatives". J Mass Dent Soc. 2007 Fall;56(3):44-5.
3	FDA Approved Drug Products: Oxazepam oral capsules
4	BDDCS applied to over 900 drugs
5	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
6	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7	Health Canada Product Monograph: Oxazepam oral tablets
8	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9	Effects of the combination of metyrapone and oxazepam on cocaine and food self-administration in rats. Pharmacol Biochem Behav. 2008 Nov;91(1):181-9.
10	Bioreactor systems in drug metabolism: synthesis of cytochrome P450-generated metabolites. Metab Eng. 2000 Apr;2(2):115-25.
11	Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion. Br J Clin Pharmacol. 2009 Nov;68(5):721-30.
12	Cytochrome P450 enzyme activity and protein expression in primary porcine enterocyte and hepatocyte cultures. Xenobiotica. 2000 Jan;30(1):27-46.
13	Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. Drug Metab Dispos. 2002 Nov;30(11):1257-65.
14	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
15	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
16	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
17	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
18	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
19	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
20	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
21	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
22	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
23	Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
24	Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
25	Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
26	UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
27	Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
28	Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
29	Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
30	Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
31	Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
32	Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
33	Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
34	Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
35	Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
36	Drug Interactions Flockhart Table
37	Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
38	Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
39	Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
40	Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
41	Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
42	The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
43	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
44	Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
45	The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
46	Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet. 1997 Mar;32(3):194-209.
47	Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers. Clin Pharmacol Ther. 2002 Nov;72(5):505-13.
48	Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of ethosuximide by human hepatic microsomal enzymes. Xenobiotica. 2003 Mar;33(3):265-76.
49	cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol Pharmacol. 2001 Feb;59(2):386-92.
50	Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol. 2014 Jan;10(1):107-22.
51	Determination of UDP-glucuronosyltransferase UGT2B7 activity in human liver microsomes by ultra-performance liquid chromatography with MS detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jul 1;870(1):84-90.
52	Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther. 2008 Apr;83(4):595-600.
53	PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
54	Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168.
55	Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
56	Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
57	Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
58	Translocator protein (18 kDa) mediates the pro-growth effects of diazepam on Ehrlich tumor cells in vivo. Eur J Pharmacol. 2010 Jan 25;626(2-3):131-8.
59	Comparison of five benzodiazepine-receptor agonists on buprenorphine-induced mu-opioid receptor regulation. J Pharmacol Sci. 2009 May;110(1):36-46.
60	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
61	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2879).
62	Effects of benzodiazepines and non-benzodiazepine compounds on the GABA-induced response in frog isolated sensory neurones. Br J Pharmacol. 1989 Nov;98(3):735-40.
63	New hypnotics: perspectives from sleep physiology. Vertex. 2007 Jul-Aug;18(74):294-9.
64	Chun AH, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD "Effect of antacids on absorption of clorazepate." Clin Pharmacol Ther 22 (1977): 329-35. [PMID: 19188]
65	US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
66	US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
67	Cerner Multum, Inc. "Australian Product Information.".
68	Backman JT, Olkkola KT, Ojala M, Laaksovirta H, Neuvonen PJ "Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin." Epilepsia 37 (1996): 253-7. [PMID: 8598183]
69	Abernethy DR, Greenblatt DJ, Ameer B, Shader RI "Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation." J Pharmacol Exp Ther 234 (1985): 345-9. [PMID: 4020675]
70	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
71	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
72	Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
73	Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
74	Product Information. Gattex (teduglutide). NPS Pharmaceuticals, Bedminster, NJ.
75	Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
76	van Hecken AM, Tjandramaga TB, Verbesselt R, de Schepper PJ "The influence of diflunisal on the pharmacokinetics of oxazepam." Br J Clin Pharmacol 20 (1985): 225-34. [PMID: 4041343]
77	Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
78	Kerin NZ, Aragon E, Faitel K, Frumin H, Rubenfire M "Long-term efficacy and toxicity of high- and low-dose amiodarone regimens." J Clin Pharmacol 29 (1989): 418-23. [PMID: 2661600]